Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Target therapy for CML--applying maxizyme].

K Tani1

  • 1Institute of Medical Science, University of Tokyo.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External dose measurements to investigate the body-size dependence of personal dosemeter responses in areas affected by the Fukushima Daiichi nuclear accident.

Radiation protection dosimetry·2023
Same author

Effectiveness of simplified dose estimation equations for triage after criticality accident-a case study of dose assessment in the JCO criticality accident.

Radiation protection dosimetry·2023
Same author

Source efficiency of alpha-emitters applied to the skin surface.

Radiation protection dosimetry·2023
Same author

Intraoperative hypertensive crisis in a dog with functional paraganglioma of the gall bladder.

The Journal of small animal practice·2023
Same author

New evidence for the Ontong Java Nui hypothesis.

Scientific reports·2023
Same author

Clinical relationship between histopathological necrotic/partial necrotic findings and disease condition of gallbladder mucoceles in dogs.

Polish journal of veterinary sciences·2022
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Hammerhead ribozymes are ineffective for leukemia gene therapy due to specific cleavage site requirements. Maxizymes offer a new strategy for targeting chimeric genes in leukemia treatment.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Biochemistry

Context:

  • Leukemia gene translocation presents a challenge for traditional RNA-cleaving ribozymes.
  • Hammerhead ribozymes require specific GUC triplets, often absent in translocated genes.
  • Current therapeutic strategies for leukemia with gene translocations are limited.

Purpose:

  • To explore novel therapeutic strategies for leukemia involving gene translocations.
  • To evaluate the potential of Maxizymes in targeting chimeric genes.
  • To address the limitations of existing ribozyme applications in gene therapy.

Summary:

  • Hammerhead ribozymes are not suitable for leukemia gene therapy because they require specific RNA sequences (GUC triplets) not always present at translocation sites.

Related Experiment Videos

  • Maxizymes, a novel class of heterodimeric shortened ribozymes, are theoretically capable of cleaving any chimeric gene at the translocation site.
  • This review highlights promising results for applying the Maxizyme system to treat chronic myelogenous leukemia with bcr/abl gene translocation.

    • Impact:

    • Maxizymes could revolutionize leukemia treatment by enabling targeted gene therapy for translocation-associated leukemias.
    • This approach offers a potential new avenue for treating chronic myelogenous leukemia (CML).
    • Successful application of Maxizymes could lead to more effective and specific therapies for genetic disorders.